Alizé Pharma SAS has a diverse and seemingly incongruous portfolio that includes an unacylated ghrelin analog (UAG) aimed at Prader-Willi syndrome and type 2 diabetes, a pegylated recombinant L-asparaginase to treat acute lymphoblastic leukemia (ALL) and a rare disease program with an as-yet undisclosed target. But that doesn’t mean the programs compete with each other.